Browse our 650+ Publications​

Latest Publications

Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.

Usmani SZ, et al.
Blood Advances
May 2023
Authors and Affiliates
Saad Z. Usmani,1 Hang Quach,2 Maria-Victoria Mateos,3 Ola Landgren,4 Xavier Leleu,5 David Siegel,6 Katja Weisel,7 Xiaomei Shu,8 Chuang Li,9 Meletios Dimopoulos10 1Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; 2University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia; 3University Hospital Salamanca/ISAI, Salamanca, Spain; 4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States of America; 5CHU de Poitiers – La Miletrie/INSERM CIC 1402, Poitiers, France; 6John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, United States of America; 7University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8Paraxel, Chengdu, China; 9Amgen Inc., Thousand Oaks, CA, United States of America; 10National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Martin T, et al.
Blood Cancer Journal
May 2023
Authors and Affiliates
Thomas Martin 1,22, Meletios-Athanasios Dimopoulos 2, Joseph Mikhael 3, Kwee Yong 4, Marcelo Capra5, Thierry Facon6,Roman Hajek 7, Ivan Špička8, Ross Baker9, Kihyun Kim10, Gracia Martinez11, Chang-Ki Min12, Ludek Pour13, Xavier Leleu 14, Albert Oriol 15, Youngil Koh16, Kenshi Suzuki17, France Casca18, Sandrine Macé19, Marie-Laure Risse20 and Philippe Moreau21,22 1Department of Hematology, University of California at San Francisco, San Francisco, CA, USA. 2The National and Kapodistrian University of Athens, Athens, Greece. 3Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 4Department of Haematology, University College Hospital, London, UK. 5Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 6Department of Haematology, Lille University Hospital, Lille, France. 7Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. 8Department of Hematology, 1st Faculty of Medicine, Charles University andGeneral Hospital, Prague, Czech Republic. 9Perth Blood Institute, Murdoch University, Perth, Australia. 10Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 11Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo,Brazil. 12Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea. 13Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 14Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm, 1402 Poitiers Cedex, France. 15Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain. 16Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. 17Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan. 18Ividata Life Science, Levallois-Perret, France. 19Sanofi, R&D, Chilly-Mazarin, France. 20Sanofi, R&D, Vitry-sur-Seine, France. 21Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. 22These authors contributed equally: Thomas Martin, PhilippeMoreau

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

Patel DA, et al.
April 2023
Authors and Affiliates
Dilan A. Patel, Fei Wan, Kathryn Trinkaus, Daniel G. Guy, Natasha Edwin, Marcus Watkins, Nancy L. Bartlett, Amanda Cashen, Todd A. Fehniger, Armin Ghobadi, Neha-Mehta Shah, Brad S. Kahl Washington University in St Louis School of Medicine, St Louis, MO, 63110

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Frigault MJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Matthew J. Frigault,1,2 Michael R. Bishop,3 Jacalyn Rosenblatt,4 Elizabeth K. O’Donnell,1,2 Noopur Raje,1,2 Daniella Cook,1,2 Andrew J. Yee,1,2 Emma Logan,4 David E. Avigan,4 Andrzej Jakubowiak,3 Kit Shaw,5 Heather Daley,5 Sarah Nikiforow,5 Faith Griffin,6 Christine Cornwell,6 Angela Shen,6 Christopher Heery,6 and Marcela V. Maus1,2 1Massachusetts General Hospital Cancer Center, Boston, MA; 2Harvard Medical School, Boston, MA; 3David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL; 4Beth Israel Deaconess Medical Center, Boston, MA; 5Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA; and 6Arcellx, Inc., Gaithersburg, MD

Impact of BCG vaccination on the repertoire of human γδ T cell receptors

Xia M, et al.
April 2023
Authors and Affiliates
Mei Xia 1, Azra Blazevic 1, Andrew Fiore-Gartland 2, Daniel F Hoft 1,3; 1 Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States. 2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 3 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States.

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

Pai JA, et al.
April 2023
Authors and Affiliates
Joy A Pai 1, Matthew D Hellmann 2, Jennifer L Sauter 3, Marissa Mattar 4, Hira Rizvi 5, Hyung Jun Woo 6, Nisargbhai Shah 7, Evelyn M Nguyen 8, Fathema Z Uddin 7, Alvaro Quintanal-Villalonga 7, Joseph M Chan 7, Parvathy Manoj 7, Viola Allaj 7, Marina K Baine 3, Umesh K Bhanot 9, Mala Jain 9, Irina Linkov 9, Fanli Meng 6, David Brown 6, Jamie E Chaft 10, Andrew J Plodkowski 11, Mathieu Gigoux 12, Helen H Won 6, Triparna Sen 10, Daniel K Wells 13, Mark T A Donoghue 6, Elisa de Stanchina 4, Jedd D Wolchok 14, Brian Loomis 6, Taha Merghoub 14, Charles M Rudin 15, Andrew Chow 16, Ansuman T Satpathy 17; 1 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA. 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cancer Biology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 11 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Santa Ana Bio, Alameda, CA, USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chowa1@mskcc.org. 17 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, Stanford University, Stanford, CA, USA. Electronic address: satpathy@stanford.edu.

Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders

John J, et al.
April 2023
Authors and Affiliates
Jessy John 1, Samantha M Y Chen 2, Rachel A Woolaver 2, Huaibin Ge 1, Monika Vashisht 1, Ziyu Huang 3, Zhangguo Chen 1, Jing H Wang 1,4; 1 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 2 Department of Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, CO, United States. 3 UPMC Hillman Cancer Center Biostatistics Facility, University of Pittsburgh, Pittsburgh, PA, United States. 4 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States.

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov E, et al.
April 2023
Authors and Affiliates
Eugene Shenderov 1,2, Angelo M De Marzo 3,4,5, Tamara L Lotan 3,4,5, Hao Wang 6, Sin Chan 3, Su Jin Lim 6, Hongkai Ji 7, Mohamad E Allaf 5, Carolyn Chapman 3, Paul A Moore 8, Francine Chen 8, Kristina Sorg 9, Andrew M White 9, Sarah E Church 9, Briana Hudson 9, Paul A Fields 10, Shaohui Hu 11, Samuel R Denmeade 3, Kenneth J Pienta 3, Christian P Pavlovich 5, Ashley E Ross 12, Charles G Drake 13, Drew M Pardoll 3,14, Emmanuel S Antonarakis 3,14,15; 1 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 3 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5 Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6 Department of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8 MacroGenics, Inc., Rockville, MD, USA. 9 NanoString Technologies Inc., Seattle, WA, USA. 10 Adaptive Biotechnologies, Seattle, WA, USA. 11 CDI Labs, Baltimore, MD, USA. 12 Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 13 Immuno-Oncology, Janssen, Horsham, PA, USA. 14 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. 15 University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.

T cell immunity is key to the pandemic endgame: How to measure and monitor it

Schwarz M, et al,
April 2023
Authors and Affiliates
Megan Schwarz 1,2, Slim Mzoughi 1,2, Daniel Lozano-Ojalvo 3, Anthony T Tan 4, Antonio Bertoletti 4, Ernesto Guccione 1,2,5; 1 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA. 2 Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. 3 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, NY, USA. 4 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. 5 Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.